Q2 2026 Siemens Healthineers AG Earnings Call Transcript
Key Points
- Siemens Healthineers AG (SMMNY) reported strong operational performance in its Imaging and Precision Therapy segments, with a 6% growth in the first half of fiscal 2026.
- The company is preparing for a strategic carve-out of its Diagnostics business to create further optionality and flexibility for future development paths.
- Siemens Healthineers AG (SMMNY) is implementing a comprehensive generational change in its leadership team, bringing in new talent to drive future success.
- The company has a strong equipment order book with a book-to-bill ratio of 1.02, indicating healthy demand for its products.
- Siemens Healthineers AG (SMMNY) is well-prepared for its upcoming spin-off from Siemens, with a banking consortium in place for debt financing and liquidity management.
- The Diagnostics segment faced significant challenges, particularly in China, leading to a 6% revenue decline due to structural market rebasing and reimbursement reductions.
- Foreign exchange and tariff headwinds negatively impacted the company's margins by approximately 200 basis points.
- The company updated its fiscal 2026 outlook, lowering its revenue growth expectations to 4.5% to 5% due to challenges in the Diagnostics segment.
- Additional inflation in the supply chain, particularly in memory chips and logistics, is expected to impact earnings, leading to a revised EPS range of EUR2.20 to EUR2.30.
- The Diagnostics segment is undergoing a transformation, which is currently muting growth due to the transition from legacy platforms to the Atellica platform.
As a reminder, this conference is being recorded. Before we begin, I would like to draw your attention to the safe harbor statement on Page 2 of the Siemens Healthineers presentation. These statements are based on the company's current expectations and certain assumptions and are, therefore, subject to certain risks and uncertainties. At this time, I would like to turn the call over to your host today, Mr. Marc Koebernick, Head of Investor Relations. Please go ahead, sir.
Thank you, operator. Good morning, and welcome to our Q2 earnings call for fiscal 2026. I'd like to thank each of you for joining us today. This morning at 7:00 a.m., we published our Q2 2026 results. All related materials for today's results release are available on the IR section of the Siemens Healthineers web page.
In a moment, we'll hear directly from our CEO, Bernd Montag; and our CFO, Jochen Schmitz. And after their presentations, as usual, we have a Q&A session.
(Event Instructions)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
